On June 3, 2025, the FDA granted Fast Track designation to CHM-CDH17, a third-generation CAR-T therapy targeting CDH17 for ...

Cabozantinib, a tyrosine kinase inhibitor (TKI), was recently approved for patients with previously treated pancreatic NETs.

A new study reveals that small cell lung cancer (SCLC) likely begins in basal stem-like cells rather than in neuroendocrine ...

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will unveil ...

Exelixis (EXEL) stock wins a Buy at Goldman Sachs based on potential of its lead asset, zanzalintinib, ahead of a patent ...

Findings from a new study by Duke researchers are shifting the way one of the deadliest forms of lung cancer is understood and offering fresh insights that could revolutionize treatment approaches.

NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced that the company’s abstract featuring first clinical data from ...

A doctor at an Overland Park hospital made history performing the area's first non-invasive liver tumor treatment.

Appendix cancer, once considered rare, is increasingly affecting younger adults, particularly those born since the 1970s.

A new study reveals that small cell lung cancer (SCLC) likely begins in basal stem-like cells rather than in neuroendocrine cells ...

Novartis (Switzerland) is a global pharmaceutical leader and one of the pioneers in advancing radioligand therapy (RLT). The ...

The global Radioligand Therapy (RLT) Market, valued at US$2.36 billion in 2024, stood at US$3.15 billion in 2025 and is projected to advance ...